课题基金 / 基金详情

BETA CATENIN IN PROSTATE CANCER

BETA CATENIN IN PROSTATE CANCER
β-连环蛋白在前列腺癌中的作用
批准号:
6378100
负责人:
Edward P Gelmann
金额:
$15.6万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-07-01 至 2003-06-30

项目摘要

项目成果

Edward P Gelmann的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Applicant's Abstract): Beta-Catenin is a bifunctional molecule that mediates the connection between the cell surface adhesion molecule Ecadherin and the acting cytoskeleton and also is a partner of T cell factor (TCF) family molecules in forming a heterodimeric transcription factor that mediates signaling from Wnt receptors. beta-Catenin signaling is activated in many cancers by mutation of beta-catenin or by inactivation of beta-catenin-binding molecules. The effects of these oncogenic events are to decrease intracytoplasmic degradation and increase the availability of beta-catenin to carry out its transcriptional function. We have found mutations of the beta-catenin gene in primary prostate cancer tissues, thereby showing that beta-catenin signal transduction is activated in at least some prostate cancer cases. A second potential mechanism for beta-catenin activation in prostate cancer is loss of E-cadherin expression that occurs in approximately half of prostate cancers and is associated with poor prognosis. Our preliminary data suggest that one mechanism by which beta-catenin contributes to prostate cancer promotion and progression is by interacting with the androgen receptor and increasing transcriptional activation by androgen, the essential hormone for prostate cancer growth. Our hypothesis is that beta-catenin activation contributes to prostate cancer progression in part by augmenting androgen-driven gene transcription. This proposal focuses on determining the mechanism of molecular interaction between beta-catenin and androgen receptor. The experiments will attempt to demonstrate a direct interaction between recombinant androgen receptor and beta-catenin proteins. We will map the regions of interaction by deletion analysis and site-directed mutagenesis. We will also determine if E-cadherin binding interferes directly with the region of beta-catenin that binds to androgen receptor. These experiments will establish a linkage between steroid hormone receptor signaling and Wnt signaling. This will set the stage for more comprehensive study of the interaction between androgen action and the Wnt signaling pathway that is mediated by beta-catenin/TCFdriven transcription.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/s0025-6196(19)30639-1
发表时间: 2000
期刊: Mayo Clinic proceedings
影响因子: 8.9
作者: [Gail S. Prins]
通讯作者: Gail S. Prins
DYRK1B Inhibition for Prostate Cancer
  • 批准号:
    10665942
  • 项目类别:
  • 资助金额:
    $15.35万
  • 财政年份:
    2023
  • 负责人:
    Edward P Gelmann
  • 依托单位:
CRMO- CLINICAL RESEARCH MANAGEMENT OFFICE
Role of the DNA Damage Response in Prostate Cancer Initiation
CRMO- CLINICAL RESEARCH MANAGEMENT OFFICE
国内基金
海外基金
增生性玻璃体视网膜病变早期钙黏蛋白(Cadherins)异常表达启动视网膜色素上皮细胞游离的分子机制
  • 批准号:
    81770939
  • 项目类别:
    面上项目
  • 资助金额:
    56.0万元
  • 批准年份:
    2017
  • 负责人:
    王方
  • 依托单位:
Beta-catenin/Cadherins, EphBs 在平衡颅神经嵴细胞的粘附和迁徙机制的研究
  • 批准号:
    81400494
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    23.0万元
  • 批准年份:
    2014
  • 负责人:
    刘人恺
  • 依托单位:
Cadherins与nectins在青少年期慢性社会应激损害小鼠前额叶形态可塑性与功能中的作用
  • 批准号:
    81401129
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    23.0万元
  • 批准年份:
    2014
  • 负责人:
    李继涛
  • 依托单位: